In VivoPharma appears to be at the dawn of a transformative era in space-based research. From leveraging microgravity effects to biomanufacturing in orbit for ultra-pure biologics, industry is exploring a ho
ScripQ2 Earnings Picture Darkens Big pharma earnings season started off well, but things changed towards the end of the second week, when Sanofi announced its financial results. Sanofi’s report triggered s
ScripPfizer and Astellas’s antibody-drug conjugate (ADC) Padcev (enfortumab vedotin) could more than double the size of its addressable population if it can repeat the success it showed in combination with
ScripLooking across the drugs with the top forecast sales for 2030, according to Evaluate data, there are many traits that apply across the board. Superior efficacy and safety will always be the top driv